Regeneron Pharmaceuticals (NASDAQ:REGN) witnessed a selling pressure and the shares last traded with a loss of -7.05 points or -2% at $345.61. Investors jumped in to buy the shares on weakness. The net money flow till latest update was calculated at $2.45 million with an inflow of $41.76 million in upticks and an outflow of $39.31 million in downticks. Using the data, the up/down ratio is found to be 1.06. The share price has recorded -2.43% on a weekly basis.A block trade of $6.49 million in uptick and $0 million in downtick was also observed, resulting in an up/down ratio of 0. The net money flow of the block trade stood at a $6.49, signaling heavy buying.
The stock has recorded a 20-day Moving Average of 10.37% and the 50-Day Moving Average is 11.15%. The company shares have dropped 32.32% in the past 52 Weeks. On August 4, 2015 The shares registered one year high of $605.93 and one year low was seen on March 17, 2016 at $348.96. The 50-day moving average is $382.04 and the 200 day moving average is recorded at $421.93. S&P 500 has rallied 1.93% during the last 52-weeks.
Regeneron Pharmaceuticals (NASDAQ:REGN): The stock opened at $354.00 on Tuesday but the bulls could not build on the opening and the stock topped out at $354.00 for the day. The stock traded down to $342.78 during the day, due to lack of any buying support eventually closed down at $345.14 with a loss of -2.13% for the day. The stock had closed at $352.66 on the previous day. The total traded volume was 1,183,509 shares.
Currently the company Insiders own 10.4% of Regeneron Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -3.67% . Institutional Investors own 75.17% of Regeneron Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of -3.67%. On the companys insider trading activities, Ryan Arthur F, director of Regeneron Pharmaceuticals Inc, unloaded 1,000 shares at an average price of $396.64 on May 24, 2016. The total amount of the transaction was worth $396,640, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Companys marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.